Francis E Odonnell Jr
CIK 1066040 · Chief Executive Officer · last filed 2026-08-04
Francis E Odonnell Jr is a Chief Executive Officer who has filed 112 SEC Form 4 insider transactions across 2 companies since 2007. Across all open-market trades the lifetime net is +$7.7M, making them a net buyer over the disclosed history. 25 SEC filings were submitted jointly with ACCENTIA BIOPHARMACEUTICALS INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ABPI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
4131 PARKLAKE AVENUE, SUITE #225
RALEIGH, NC 27612
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACCENTIA BIOPHARMACEUTICALS INC (ABPI) Delisted | Chief Executive Officer | 4,349,592 | — | — | $7.91M | 10 | 2008-08-13 |
| BIODELIVERY SCIENCES INTERNATIONAL INC (BDSIW) Delisted | Director | 3,869,671 | — | — | -$233.0K | 2 | 2007-06-01 |
Recent Filings
112 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-04 | — | Grant (A) | +50,000 | $0 | |
| 2020-05-14 | — | Exer (M) | +22,500 | $0 | |
| 2020-05-08 | — | Sell (S) | −11,250 | -$51.0K | |
| 2020-05-05 | — | Sell (S) | −16,000 | -$71.2K | |
| 2020-04-22 | — | Sell (S) | −20,000 | -$84.4K | |
| 2020-03-18 | — | Mixed | +104,034 | -$250.2K | |
| 2020-02-04 | — | Sell (S) | −8,000 | -$42.5K | |
| 2020-01-03 | — | Sell (S) | −8,000 | -$48.8K | |
| 2019-12-31 | — | Mixed | — | -$50.4K | |
| 2019-12-30 | — | Sell (S) | −10,000 | -$70.0K |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.